In liver disease liver cell growth and repair are central processes in the recovery of normal structure and function. In acute liver failure where greater than 80% of the liver cell mass is destroyed by drugs or viruses' complete regeneration ofa normal liver occurs in surviving patients. In contrast the insidious cell loss found in chronic viral, alcoholic, and autoimmune disease is frequently not balanced by adequate cell replacement and coupled with a disruption of the hepatic architecture eventually leads to death from liver insufficiency. In spite of a vast literature on liver regeneration and hepatotrophic factors a clear understanding of how hepatic growth is controlled has not emerged.
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The majority of in vivo studies have focused on the partially hepatectomised rat where liver regeneration is initiated within a few hours of surgery, with rapid cell division over the first four days, and liver size restored within two to three weeks.2 Less information is available in man but recovery is generally uncomplicated when resection is carried out in a previously healthy liver either to control bleeding after trauma or for a localised tumour.3 Evidence from serial liver scans, liver biopsies and repeated laparotomy indicates that regeneration is initiated within three days and complete after about six months. Considerable effort has been made to isolate and characterise the specific hepatic regenerative stimulator substances from animals and man, including from serum of patients with liver failure. 26 The possibility is emerging that in fulminant hepatic failure an adequate response to liver cell loss, in terms of production of stimulatory factors occurs, but toxic substances present, as a result of release from the necrotic hepatic remnant and lack of detoxification of substances from the gut, inhibit or delay liver regeneration and the recovery of hepatic function.
Evidence for inhibitors of hepatic regeneration in acute liver failure Early work in the King's Liver Unit and elsewhere revealed direct toxicity of plasma from fulminant hepatic failure patients to rabbit27 and rat2" hepatocytes in monolayer culture after prolonged exposure. The effects with rabbit hepatocytes were highly potent, being apparent at 1 in 5 dilution of the plasma, and toxicity could be reduced but not eliminated by heating. When the acute effects of fulminant hepatic failure serum were examined in hepatocytes freshly isolated from both normal rat livers and 24 h after partial hepatectomy differences in response were found between the two types of cells. DNA and protein synthesis was accelerated in hepatocytes from regenerating livers to a similar extent to that observed in vivo. A specific inhibitory effect on DNA synthesis with fulminant hepatic failure serum but not with normal serum was found in regenerating hepatocytes. DNA and protein synthesis in normal hepatocytes was inhibited by normal serum, the inhibition being less with fulminant hepatic failure serum.29 Cell integrity was not affected in these short incubations suggesting that cytotoxicity may take longer to develop. The differences in response to fulminant hepatic failure serum ofDNA synthesis in normal and regenerating hepatocytes may either be a reflection ofincreased sensitivity ofthe regenerating hepatocyte to toxic substances or the greater ability of normal hepatocytes to detoxify these substances. The To further characterise the nature of the inhibitory factors experiments have been performed using rat hepatocytes in primary culture in the presence of epidermal growth factor and insulin.33 Fulminant hepatic failure serum ultrafiltrates (<10 kD) significantly inhibited incorporation of 3H-thymidine into DNA to 2-7% SD (4 7)% of control value. This effect was dose dependent, reversible and was not associated with an increase in lactate dehydrogenase release. Column chromatography on Sephadex G-25 gel produced two peaks of inhibitory activity corresponding to apparent molecular weights of 2 kD and 5 kD. Possible interaction of small lipophilic molecules with the dextran gel could cause retardation and lead to elution at a position corresponding to a greater molecular size.
Identity of the inhibitory substances While the identity of the factors responsible for the inhibitory effects is not known there are a number of groups of substances which could be involved. It seems unlikely that 'endogenous' inhibitors of liver cell growth, whose role is to limit liver growth to normal size, would be secreted or activated inappropriately, although the release of sequestered pools from necrotic liver tissue remains a possibility.
One of the characteristic features of liver failure is the accumulation of a wide range of toxic substances in the circulation. These may interfere directly with the process of liver regeneration or indirectly through effects on energy metabolism as discussed earlier. Zeive et al have performed a number of studies with ammonia, octanoate, and mercaptans which are known to accumulate in liver failure and have also been shown to have toxic effects in the brain. Liver thymidine kinase activity and the incorporation of 3H-thymidine into hepatic DNA were depressed after repeated injection of these compounds into rats after partial hepatectomy. 34 The effects were reversible but the mechanisms involved were not investigated. In further experiments the effects of these toxins were studied with liver injury caused by acetaminophen35 and galactosamine.-6 Greater depression of hepatic thymidine kinase and ornithine decarboxylase activities was seen after centrilobular damage from paracetamol.
A number of the inflammatory mediators and cytokines produced by monocytes and macrophages in response to stimulation by endotoxin have been shown to affect DNA synthesis. Patients with acute liver failure frequently develop bacterial infections3 with increased release and production of cytokines including tumour necrosis factor. The dose dependent effects of interleukins 1, 2 and 6 (IL-1, IL-2, IL-6) on DNA synthesis in adult rat hepatocytes in primary culture stimulated by insulin and epidermal growth factor have been investigated.37 Significant inhibition of DNA synthesis by IL-1 and to a lesser extent IL-6, but not IL-2 or tumour necrosis factor was found. IL-1 production38 and serum IL-6 concentration39 have been shown to be significantly increased in patients with liver failure, suggesting their possible importance in influencing liver regeneration in this condition. These cytokines may be responsible for counteracting the effects of stimulatory substances in the >10 kD fraction as is suggested by the in vitro and in vivo experiments, as discussed above, as their molecular weights are 17 kD to 22 kD respectively. They would not appear in the 'toxic' <10 kD ultrafiltrate fraction of fulminant hepatic failure serum, however, which had the acute direct inhibitory effects on DNA synthesis in these experiments.
Hepatocyte growth factor One of the most recent significant developments has been the purification and characterisation of hepatocyte growth factor. Three independent groups, two from Japan and one from the'USA have isolated hepatocyte growth factor from different sources. Hepatocyte growth factor is species non-specific and substances with a similar structure have been purified from rat platelets,' rabbit serum and normal human plasma4' and plasma from patients with fulminant hepatic failure. 42 The human material (hHGF) is a heterodimer with molecular weight ranging between 79 kD to 86 kD and consists of two polypeptide chains, heavy and light, linked together by disulphide bonds. Hepatocyte growth factor is a heparin binding growth factor and is distinct from other known hepatocyte growth factors such as insulin, epidermal growth factor and TGFa. It is the most potent mitogen for hepatocytes in primary culture and has synergistic effects with insulin, glucagon and epidermal growth factor. Using molecular cloning techniques it has been possible to obtain the nucleotide sequence of hHGF by cloning hepatocyte growth factor cDNA and thus deduce its aminoacid structure.43" There is considerable homology of hepatocyte growth factor with serine proteases, particularly plasminogen, but the significance of this is unknown.
With biological and ELISA assays, it was shown that the blood concentrations of hepatocyte growth factor are increased in patients with fuhminant hepatic failure with the highest levels being found in patients with deep encephalopathy and those who died. This suggests that the stimulus to liver regeneration may be adequate, but the response is impaired. The next step is to isolate and characterise hHGF receptors and define the intracellular processes which lead to promotion ofhepatocyte DNA synthesis and cell division. It is possible that these mechanisms are disrupted in patients with fulminant hepatic failure. With the availability ofpure recombinant hHGF it will be important to perform in vivo experiments on the stimulatory effects ofhepatocyte growth factor on hepatic DNA synthesis, as to date all data have been obtained using hepatocyte culture. This will be essential to evaluate the therapeutic potential of hepatocyte growth factor, as a hepatotrophic treatment in patients with liver failure.
The site of production of hepatocyte growth factor is fundamental to the understanding of its function. A number of studies have been performed on this using either immunochemical S94 group.bmj.com on November 7, 2017 -Published by http://gut.bmj.com/ Downloaded from techniques, Northern blotting or in situ hybridisation and the results may have been influenced by the method used. Different sites other than the liver have been identified which seem to vary according to the nature of the liver injury and the species studied and include the spleen, lung, brain and kidney. In the light of number of tissues synthesising hepatocyte growth factor, it is likely that it may affect other epithelial cells than those in the liver. From experiments in rats with liver injury caused by galactosamine or carbon tetrachloride the non-parenchymal cells in the liver, particularly the Kupffer cells appear to be the main site of hepatocyte growth factor synthesis, consistent with a paracrine mechanism of hepatocyte growth factor action. 45 As yet no equivalent information on the site of hepatocyte growth factor production has been obtained in man.
Although hepatocyte growth factor is the most potent hepatocyte growth factor it is not clear if other factors are required for the process of liver regeneration. The hepatic stimulatory effects of another novel growth factor, which appears to be bilirubin covalently bound to serum albumin (biliprotein), have been reported. 46 The plasma levels of this complex were investigated in patients during the course of fulminant hepatic failure. Biliprotein levels expressed as a percentage of total bilirubin were significantly higher on admission and rose subsequently in patients who survived compared with those who died. 47 The role of biliprotein in the recovery of liver function needs to be further elucidated.
Future directions Liver regeneration is clearly under multifactorial control throughout all stages. The initial signal which starts the process remains to be identified, although there is still the possibility that it may simply be a response to Identification and characterisation of the inhibitory factors present in the circulation in acute liver failure will also help in understanding how liver growth and regeneration is controlled.
In fulminant hepatic failure the increased circulating concentrations of stimulator substances which have been described imply that liver regeneration is already initiated. In at least some groups ofpatients, and possibly all, there is evidence that liver regeneration is delayed or that an adequate regenerative response does not occur. Whether infusion of recombinant hHGF and/or other stimulator substances will improve the response in these patients remains to be seen.
An alternative approach to the treatment of liver failure is the use of heterotopic liver transplantation or the use of extracorporeal 'hepatocyte reactors' to provide temporary liver support while the patient's own liver recovers. The presence ofan intact functioning liver, or equivalent hepatocyte mass, could possibly reduce the regenerative response in the host organ. The relationship between the host and donor liver will provide further insight into the control mechanisms involved in liver regeneration. 
